CMV PED Study - A Retrospective Observational Study to Understand the Clinical and Economic Burden of Cytomegalovirus Reactivation in Pediatric Patients Receiving Allogeneic Hematopoietic Stem Cell Transplantation in Italy

What this Trial Is About

Researchers are conducting an observational retrospective study to better understand the clinical and economic impact of Cytomegalovirus (CMV) reactivation in children who have undergone allogeneic Hematopoietic Stem Cell Transplantation (HSCT) in Italy. This study aims to provide valuable information to clinicians, payers, and guideline committees to improve management and care for pediatric patients facing this condition. The study involves reviewing medical records from several major pediatric centers in Italy that perform most of the allogeneic HSCT procedures. Data will be collected for patients who received HSCT between January 2018 and June 2020, with a follow-up period of up to 12 months for each patient. Researchers will analyze factors such as patient characteristics, treatment patterns, and use of healthcare resources related to CMV infection. Participants' medical charts, both electronic and paper, from inpatient and outpatient settings will be examined to gather information on baseline demographics, CMV serostatus, donor type, stem cell source, conditioning intensity, and immunosuppression use. The study will also look at CMV management practices during the first year after transplant, infection rates, complications, hospitalizations, and mortality. No new treatments will be given, and participation involves data collection only. The study will end in July 2026.

Burden of Cytomegalovirus Reactivation in Pediatric Patients After Allogeneic Hematopoietic Stem Cell Transplantation